How Solomon was paid
$1.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Other | Total |
|---|---|---|---|---|---|
| Jonathan SolomonChief Executive Officer | $453,317 | $70,725 | $639,338 | $211,642 | $1,375,022 |
| Marina WolfsonChief Financial Officer | $249,102 | $38,248 | $164,765 | $101,339 | $553,454 |
| Dr. Merav BassanChief Development Officer | $285,009 | $44,415 | $165,609 | $147,297 | $642,330 |
What changed and why
- $1.4M$1,375,022 was the CEO’s 2025 total compensation, versus $1,078,592 in 2024.
- 40%40% to 50% of salary was the stated annual performance-bonus eligibility range.
- No performance-based bonuses were paid to named executive officers for fiscal 2025.
- Three months’ salary cash payments were approved for each named executive officer and included in 2025 All Other Compensation.
- 2025 RSUs were fully vested and issued on their grant date without continued-service conditions.
Other BiomX proxy statements
- 2025 proxy statement
Jonathan Solomon paid $1.1M (-4% on the year).
Filed Aug 28, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.